Home LiteratureArticle Details
PMID: 10618417 Published · ppublish English Clinical Trial Journal Article Research Support, U.S. Gov't, P.H.S.

Pronounced and sustained central hypernoradrenergic function in major depression with melancholic features: relation to hypercortisolism and corticotropin-releasing hormone.

Wong ML, Kling MA, Munson PJ, Listwak S, Licinio J, Prolo P, Karp B, McCutcheon IE, Geracioti TD, DeBellis MD, Rice KC, Goldstein DS, Veldhuis JD, Chrousos GP, Oldfield EH, McCann SM, Gold PW

Abstract

Both stress-system activation and melancholic depression are characterized by fear, constricted affect, stereotyped thinking, and similar changes in autonomic and neuroendocrine function. Because norepinephrine (NE) and corticotropin-releasing hormone (CRH) can produce these physiological and behavioral changes, we measured the cerebrospinal fluid (CSF) levels each hour for 30 consecutive hours in controls and in patients with melancholic depression. Plasma adrenocorticotropic hormone (ACTH) and cortisol levels were obtained every 30 min. Depressed patients had significantly higher CSF NE and plasma cortisol levels that were increased around the clock. Diurnal variations in CSF NE and plasma cortisol levels were virtually superimposable and positively correlated with each other in both patients and controls. Despite their hypercortisolism, depressed patients had normal levels of plasma ACTH and CSF CRH. However, plasma ACTH and CSF CRH levels in depressed patients were inappropriately high, considering the degree of their hypercortisolism. In contrast to the significant negative correlation between plasma cortisol and CSF CRH levels seen in controls, patients with depression showed no statistical relationship between these parameters. These data indicate that persistent stress-system dysfunction in melancholic depression is independent of the conscious stress of the disorder. These data also suggest mutually reinforcing bidirectional links between a central hypernoradrenergic state and the hyperfunctioning of specific central CRH pathways that each are driven and sustained by hypercortisolism. We postulate that alpha-noradrenergic blockade, CRH antagonists, and treatment with antiglucocorticoids may act at different loci, alone or in combination, in the treatment of major depression with melancholic features.

MeSH Terms
Adrenocorticotropic Hormone/blood Adult Circadian Rhythm Corticotropin-Releasing Hormone/cerebrospinal fluid Depressive Disorder/metabolism Female Humans Hydrocortisone/blood Male Middle Aged Norepinephrine/cerebrospinal fluid Sleep Statistics as Topic Stress, Physiological
Chemicals
Adrenocorticotropic Hormone Corticotropin-Releasing Hormone Hydrocortisone Norepinephrine
Authors & Affiliations
17 authors, click to expand affiliations / ORCID
Wong M L
Clinical Neuroendocrinology Branch, National Institute of Mental Health, National Institutes of Health, Bethesda, MD 20892, USA.
Kling M A
Munson P J
Listwak S
Licinio J
Prolo P
Karp B
McCutcheon I E
Geracioti T D
DeBellis M D
Rice K C
Goldstein D S
Veldhuis J D
Chrousos G P
Oldfield E H
McCann S M
Gold P W
References (44)
44 references, click to expand
  1. Release of galanin from isolated perfused porcine adrenal glands: role of splanchnic nerves.
    Am J Physiol. 1991 Jul;261(1 Pt 1):E31-40 PMID: 1713413
  2. A rating scale for depression.
    J Neurol Neurosurg Psychiatry. 1960 Feb;23:56-62 PMID: 14399272
  3. Plasma and cerebrospinal fluid neurochemical pattern in Menkes disease.
    Ann Neurol. 1993 Feb;33(2):171-5 PMID: 8434878
  4. Lifetime and 12-month prevalence of DSM-III-R psychiatric disorders in the United States. Results from the National Comorbidity Survey.
    Arch Gen Psychiatry. 1994 Jan;51(1):8-19 PMID: 8279933
  5. Catecholamines in depression: an update.
    Clin Chem. 1994 Feb;40(2):279-87 PMID: 8313609
  6. Sympathoadrenal regulation of adrenal androstenedione release.
    Neuroendocrinology. 1994 Apr;59(4):406-12 PMID: 8202222
  7. Corticosterone effects on corticotropin-releasing hormone mRNA in the central nucleus of the amygdala and the parvocellular region of the paraventricular nucleus of the hypothalamus.
    Brain Res. 1994 Mar 21;640(1-2):105-12 PMID: 8004437
  8. Diurnal variation of cerebrospinal fluid immunoreactive corticotropin-releasing hormone levels in healthy volunteers.
    J Clin Endocrinol Metab. 1994 Jul;79(1):233-9 PMID: 8027234
  9. Increased numbers of corticotropin-releasing hormone expressing neurons in the hypothalamic paraventricular nucleus of depressed patients.
    Neuroendocrinology. 1994 Oct;60(4):436-44 PMID: 7824085
  10. Urinary free cortisol excretion in depression.
    Psychol Med. 1976 Feb;6(1):43-50 PMID: 935296
  11. Norepinephrine and 3-methoxy-4-hydroxyphenyl glycol gradients in human cerebrospinal fluid.
    Am J Psychiatry. 1977 May;134(5):565-8 PMID: 848588
  12. Factors influencing the circadian periodicity of ACTH and corticosteroids.
    Med Clin North Am. 1978 Mar;62(2):251-9 PMID: 205738
  13. The neural regulation of compensatory adrenal growth.
    Ann N Y Acad Sci. 1977 Oct 28;297:373-92 PMID: 211910
  14. Corticotropin releasing factor produces behavioural activation in rats.
    Nature. 1982 May 27;297(5864):331-3 PMID: 6978997
  15. Corticotropin-releasing factor: actions on the sympathetic nervous system and metabolism.
    Endocrinology. 1982 Sep;111(3):928-31 PMID: 7049676
  16. Intraventricular corticotropin-releasing factor enhances behavioral effects of novelty.
    Life Sci. 1982 Jul 26;31(4):363-7 PMID: 6983018
  17. Inferential statistical methods for estimating and comparing cosinor parameters.
    Chronobiologia. 1982 Oct-Dec;9(4):397-439 PMID: 7168995
  18. Corticotropin-releasing factor is a potent inhibitor of sexual receptivity in the female rat.
    Nature. 1983 Sep 15-21;305(5931):232-5 PMID: 6310414
  19. Influence of corticotropin-releasing factor on reproductive functions in the rat.
    Endocrinology. 1984 Mar;114(3):914-21 PMID: 6321146
  20. Blunted corticotropin and normal cortisol response to human corticotropin-releasing factor in depression.
    N Engl J Med. 1984 Oct 25;311(17):1127 PMID: 6090905
  21. Elevated concentrations of CSF corticotropin-releasing factor-like immunoreactivity in depressed patients.
    Science. 1984 Dec 14;226(4680):1342-4 PMID: 6334362
  22. Responses to corticotropin-releasing hormone in the hypercortisolism of depression and Cushing's disease. Pathophysiologic and diagnostic implications.
    N Engl J Med. 1986 May 22;314(21):1329-35 PMID: 3010108
  23. CSF corticotropin-releasing hormone in depressed patients and normal control subjects.
    Am J Psychiatry. 1987 May;144(5):641-5 PMID: 3495188
  24. Effect of ganglion blockade on cerebrospinal fluid norepinephrine.
    J Neurochem. 1987 Nov;49(5):1484-90 PMID: 3668535
  25. Clinical and biochemical manifestations of depression. Relation to the neurobiology of stress (1)
    N Engl J Med. 1988 Aug 11;319(6):348-53 PMID: 3292920
  26. Catecholamine effects upon rat hypothalamic corticotropin-releasing hormone secretion in vitro.
    J Clin Invest. 1988 Sep;82(3):839-46 PMID: 2901433
  27. Method for sequential sampling of cerebrospinal fluid in humans.
    Neurosurgery. 1988 Dec;23(6):788-90 PMID: 3216983
  28. Cerebrospinal fluid immunoreactive corticotropin-releasing hormone and adrenocorticotropin secretion in Cushing's disease and major depression: potential clinical implications.
    J Clin Endocrinol Metab. 1991 Feb;72(2):260-71 PMID: 1846869
  29. Long-term antidepressant administration alters corticotropin-releasing hormone, tyrosine hydroxylase, and mineralocorticoid receptor gene expression in rat brain. Therapeutic implications.
    J Clin Invest. 1991 Mar;87(3):831-7 PMID: 1671867
  30. Corticosterone potentiation of conditioned fear in rats.
    Ann N Y Acad Sci. 1994 Nov 30;746:392-3 PMID: 7825895
  31. Effect of corticosterone on the enhancement of the acoustic startle reflex by corticotropin releasing factor (CRF).
    Brain Res. 1994 Dec 12;666(1):93-8 PMID: 7889373
  32. The identification and validation of distinct depressive syndromes in a population-based sample of female twins.
    Arch Gen Psychiatry. 1996 May;53(5):391-9 PMID: 8624182
  33. The maternal hypothalamic-pituitary-adrenal axis in the third trimester of human pregnancy.
    Clin Endocrinol (Oxf). 1996 Apr;44(4):419-28 PMID: 8706308
  34. Role of the amygdala in the coordination of behavioral, neuroendocrine, and prefrontal cortical monoamine responses to psychological stress in the rat.
    J Neurosci. 1996 Aug 1;16(15):4787-98 PMID: 8764665
  35. Bone mineral density in women with depression.
    N Engl J Med. 1996 Oct 17;335(16):1176-81 PMID: 8815939
  36. Low cerebrospinal fluid corticotropin-releasing hormone concentrations in eucortisolemic depression.
    Biol Psychiatry. 1997 Aug 1;42(3):165-74 PMID: 9232208
  37. Effects of noradrenergic lesions on MPTP/MPP+ kinetics and MPTP-induced nigrostriatal dopamine depletions.
    J Pharmacol Exp Ther. 1997 Oct;283(1):100-7 PMID: 9336313
  38. Locus coeruleus lesions decrease norepinephrine input into the medial preoptic area and medial basal hypothalamus and block the LH, FSH and prolactin preovulatory surge.
    Brain Res. 1997 Sep 5;767(2):289-96 PMID: 9367260
  39. Inferential statistical method for analysis of nonsinusoidal hybrid time series with unequidistant observations.
    Chronobiol Int. 1998 Mar;15(2):191-204 PMID: 9562923
  40. Intraadrenal interactions in the regulation of adrenocortical steroidogenesis.
    Endocr Rev. 1998 Apr;19(2):101-43 PMID: 9570034
  41. The endocrinology of melancholic and atypical depression: relation to neurocircuitry and somatic consequences.
    Proc Assoc Am Physicians. 1999 Jan-Feb;111(1):22-34 PMID: 9893154
  42. Alpha-1 noradrenergic receptor stimulation impairs prefrontal cortical cognitive function.
    Biol Psychiatry. 1999 Jan 1;45(1):26-31 PMID: 9894572
  43. Clinical review 104: Adrenocorticotropin (ACTH)- and non-ACTH-mediated regulation of the adrenal cortex: neural and immune inputs.
    J Clin Endocrinol Metab. 1999 May;84(5):1729-36 PMID: 10323408
  44. The antidepressants fluoxetine, idazoxan and phenelzine alter corticotropin-releasing hormone and tyrosine hydroxylase mRNA levels in rat brain: therapeutic implications.
    Brain Res. 1992 Feb 14;572(1-2):117-25 PMID: 1351783
Article Info
Journal
Proceedings of the National Academy of Sciences of the United States of America
Abbr.
Proc Natl Acad Sci U S A
ISSN
0027-8424
Published
2000-01-04
Pages
325-30
Language
English
Region
United States
NLM ID
7505876
PMCID
PMC26662
Subset
IM
Grants
NCRR NIH HHS · M01 RR000847 · United States
NIMH NIH HHS · MH 51853 · United States
NCRR NIH HHS · MO1 RR-00847 · United States
Analysis Services
Analysis Services

Contact

No. 2 Wenbo Road, Zhangqiu District, Jinan, Shandong

Qilu Normal University · Genelibs Bioinformatics Lab

750 Shunhua Rd, Jinan

2F, Bldg F, University Science Park

Tel: 0531-88819269

WeChat Official Account

Follow our WeChat subscription account for real-time updates and the latest in medical and biological research.


Business Email

E-mail: product@genelibs.com